Form 4: Regentis Biomaterials CEO Receives Stock Grant
Insider Transaction (Form 4)
Ehud Geller, Chief Executive Officer and a Director of Regentis Biomaterials Ltd., received 31,250 shares of common stock on July 9, 2026.
Summary
- Grant/award: acquired 31,250 Warrants to purchase ordinary shares on July 9, 2026; holds 31,250 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Ehud Geller — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-09 | Grant/award | Warrants to purchase ordinary shares | 31,250 | — | — | 31,250 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-09 | Grant/award (31,250 shares) |
Keywords
insider transaction, Form 4, RGNT, REGENTIS BIOMATERIALS LTD., neutral, Ehud Geller
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.